NICE: Multiple sclerosis (relapsing-remitting) -fingolimod

English: This slide shows the global prevalence of multiple sclerosis. Deutsch: Geographische Verteilung der Multiple Sklerose Česky: Geografické rozšíření roztroušené sklerózy (Photo credit: Wikipedia)

• View the summary and implementation tools
  
  treatment of highly active relapsing?remitting multiple sclerosis in adults, only if: they have an unchanged or increased relapse rate
  Clinical effectiveness 4.6 The Committee noted that only part of the population covered by the marketing authorisation for fingolimodwas considered in the manufacturer's submission, that is, people with highly active relapsing

  2 The technology 2.1 Fingolimod (Gilenya, Novartis Pharmaceuticals UK) is a sphingosine-1-phosphate receptor modulator that prevents lymphocytes from crossing the blood?brain barrier and causing damage to nerve cells in the brain and spinal cord
• The summary of the in development technology appraisal on Multiple sclerosis (primary-progressive) - fingolimod [ID62]. It links to the key documents, details of NICE staff and external stakeholders involved in developing NICE guidance.